Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Buffered vs Unmodified Ursodiol in Liver Disease
NCT00004315Phase 2Unknown
- Sponsor
- National Center for Research Resources
- Start
- Nov 1995
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ursodeoxycholic acid in cholestatic liver disease (CLD) and cystic fibrosis-associated liver disease (CFLD), sponsored by National Center for Research Resources. Primary endpoint: Bioavailability of ursodiol formulations. Status: unknown.
02
Drugs
ursodeoxycholic acid
03
Conditions
cholestatic liver disease (CLD)cystic fibrosis-associated liver disease (CFLD)
Beyond the preview
Go deeper on NCT00004315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004315.